SCHEMBL13643403

SCHEMBL13643403

COc1cc(/C=C\c2cc(CO)c(CO)c(OC)c2)cc(OC)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.56
▸ BCR P11274 1/20 0.56
▸ TUBB1 Q9H4B7 1/20 0.51
▸ CYP3A4 P08684 2/20 0.50
▸ CYP2B6 P20813 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ PTGS1 P23219 4/20 0.49
▸ PTGS2 P35354 4/20 0.49
▸ PKM P14618 1/20 0.49
▸ MAPT P10636 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ ALOX5 P09917 8/20 0.46
▸ NFKB1 P19838 2/20 0.45
▸ PTGES O14684 2/20 0.45
▸ STAT3 P40763 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45
▸ RELA Q04206 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17145742 0.86 TUBB1 (0.50) ABL1BCRTUBB1CYP1A2NFKB1
SCHEMBL17145749 0.86 MAPT (0.55) ABL1BCRCYP3A4CYP1A2CYP2D6
SCHEMBL17145762 0.85 TUBB1 (0.49) ABL1BCRTUBB1CYP1A2NFKB1
SCHEMBL13079699 0.84 ABL1 (0.46) ABL1BCRTUBB1CYP1A2PTGS1
SCHEMBL13643390 0.84 TUBB1 (0.57) TUBB1CYP3A4CYP1A2MAPTKMT2A
SCHEMBL17145738 0.84 MMP2 (0.54) TUBB1CYP3A4CYP1A2CYP2C9PTGS1
SCHEMBL786868 0.84 TUBB1 (0.52) TUBB1PTGS1PTGS2ALOX5NFKB1
SCHEMBL10030788 0.84 TUBB1 (0.64) TUBB1PTGS1PTGS2MAPTALOX5
SCHEMBL17145737 0.83 MMP2 (0.44) ABL1BCRTUBB1CYP3A4CYP1A2
SCHEMBL17145766 0.82 RELA (0.52) ABL1BCRTUBB1CYP3A4PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883809-B2 Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-11-11 — — US disclosed
US-20120283439-A1 ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Redearch (IN) 2012-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283439-A1 ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF NDUFAF1, TOP1, COX4I1 ABL1 1426/4885BCR 1498/4885TUBB1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback